Hikma Pharmaceuticals (OTCMKTS:HKMPF) Sets New 52-Week High – Should You Buy?

Hikma Pharmaceuticals Plc (OTCMKTS:HKMPF) shares hit a new 52-week high during mid-day trading on Wednesday. The stock traded as high as $23.5850 and last traded at $23.5850, with a volume of 200 shares. The stock had previously closed at $23.41.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the stock. Citigroup reissued a “buy” rating on shares of Hikma Pharmaceuticals in a report on Wednesday, August 12th. Barclays raised shares of Hikma Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday, September 8th. One analyst has rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy”.

Hikma Pharmaceuticals Stock Performance

The business has a 50-day simple moving average of $21.80 and a 200-day simple moving average of $20.21.

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals plc is a multinational pharmaceutical company that develops, manufactures and markets a broad range of generic, branded and specialty medicines. Its portfolio includes injectable medicines, oral solid-dose products, inhalation products and other treatments used in hospitals, pharmacies and community-care settings.

The company operates through three principal businesses: Injectables, Generics and Branded Medicines. Hikma supplies injectable products to hospitals and healthcare providers, offers generic medicines primarily in the United States, and markets branded and licensed medicines across the Middle East and North Africa.